Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-4f21ade1d3a44922f890a931e55ca9a9"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-4f21ade1d3a44922f890a931e55ca9a9"/>
<resource>
<Composition>
<id value="composition-en-4f21ade1d3a44922f890a931e55ca9a9"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-4f21ade1d3a44922f890a931e55ca9a9"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-4f21ade1d3a44922f890a931e55ca9a9</b></p><a name="composition-en-4f21ade1d3a44922f890a931e55ca9a9"> </a><a name="hccomposition-en-4f21ade1d3a44922f890a931e55ca9a9"> </a><a name="composition-en-4f21ade1d3a44922f890a931e55ca9a9-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/1 film-coated tablet: EU/1/09/551/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - vizarsin</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="1 film-coated tablet: EU/1/09/551/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp4f21ade1d3a44922f890a931e55ca9a9"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - vizarsin"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Vizarsin is and what it is used for</li><li>What you need to know before you take Vizarsin</li><li>How to take Vizarsin</li><li>Possible side effects</li><li>How to store Vizarsin</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What vizarsin is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What vizarsin is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Vizarsin contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. It works by helping to relax the blood vessels in your penis, allowing blood to flow into your penis when you get sexually excited. Vizarsin will only help you to get an erection if you are sexually stimulated. Vizarsin is a treatment for adult men with erectile dysfunction, sometimes known as impotence. This is when a man cannot get, or keep a hard, erect penis suitable for sexual activity.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take vizarsin"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take vizarsin"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><h2 id="do-not-take-vizarsin">Do not take Vizarsin</h2><h2 id="if-you-are-allergic-to-sildenafil-or-any-of-the-other-ingredients-of-this-medicine-listed-in-section-6">If you are allergic to sildenafil or any of the other ingredients of this medicine (listed in section 6).</h2><h2 id="if-you-are-taking-medicines-called-nitrates-as-the-combination-may-lead-to-a-dangerous-fall-in-your-blood-pressure-tell-your-doctor-if-you-are-taking-any-of-these-medicines-which-are-often-given-for-relief-of-angina-pectoris-or-chest-pain--if-you-are-not-certain-ask-your-doctor-or-pharmacist">If you are taking medicines called nitrates, as the combination may lead to a dangerous fall in your blood pressure. Tell your doctor if you are taking any of these medicines which are often given for relief of angina pectoris (or chest pain ). If you are not certain, ask your doctor or pharmacist.</h2><h2 id="if-you-are-using-any-of-the-medicines-known-as-nitric-oxide-donors-such-as-amyl-nitrite--poppers--as-the-combination-may-also-lead-to-a-dangerous-fall-in-your-blood-pressure">If you are using any of the medicines known as nitric oxide donors such as amyl nitrite ( poppers ), as the combination may also lead to a dangerous fall in your blood pressure.</h2><h2 id="if-you-are-taking-riociguat-this-drug-is-used-to-treat-pulmonary-arterial-hypertension-ie-high-blood-pressure-in-the-lungs-and-chronic-thromboembolic-pulmonary-hypertension-ie-high-blood-pressure-in-the-lungs-secondary-to-blood-clots-pde5-inhibitors-such-as-vizarsin-have-been-shown-to-increase-the-hypotensive-effects-of-this-medicine-if-you-are-taking-riociguat-or-are-unsure-tell-your-doctor">If you are taking riociguat. This drug is used to treat pulmonary arterial hypertension (i.e., high blood pressure in the lungs) and chronic thromboembolic pulmonary hypertension (i.e., high blood pressure in the lungs secondary to blood clots). PDE5 inhibitors, such as Vizarsin have been shown to increase the hypotensive effects of this medicine. If you are taking riociguat or are unsure tell your doctor.</h2><h2 id="if-you-have-a-severe-heart-or-liver-problem">If you have a severe heart or liver problem.</h2><h2 id="if-you-have-recently-had-a-stroke-or-a-heart-attack-or-if-you-have-low-blood-pressure">If you have recently had a stroke or a heart attack, or if you have low blood pressure.</h2><h2 id="if-you-have-certain-rare-inherited-eye-diseases-such-as-retinitis-pigmentosa">If you have certain rare inherited eye diseases (such as retinitis pigmentosa).</h2><h2 id="if-you-have-ever-had-loss-of-vision-due-to-non-arteritic-anterior-ischaemic-optic-neuropathy-naion-warnings-and-precautions-talk-to-your-doctor-or-pharmacist-before-taking-vizarsin">If you have ever had loss of vision due to non-arteritic anterior ischaemic optic neuropathy (NAION). Warnings and precautions Talk to your doctor or pharmacist before taking Vizarsin:</h2><h2 id="if-you-have-sickle-cell-anaemia-an-abnormality-of-red-blood-cells-leukaemia-cancer-of-blood-cells-multiple-myeloma-cancer-of-bone-marrow">If you have sickle cell anaemia (an abnormality of red blood cells), leukaemia (cancer of blood cells), multiple myeloma (cancer of bone marrow).</h2><h2 id="if-you-have-a-deformity-of-your-penis-or-peyronie-s-disease">If you have a deformity of your penis or Peyronie s Disease.</h2><h2 id="if-you-have-problems-with-your-heart-your-doctor-should-carefully-check-whether-your-heart-can-take-the-additional-strain-of-having-sex">If you have problems with your heart. Your doctor should carefully check whether your heart can take the additional strain of having sex.</h2><h2 id="if-you-currently-have-a-stomach-ulcer-or-a-bleeding-problems-such-as-haemophilia">If you currently have a stomach ulcer, or a bleeding problems (such as haemophilia).</h2><p>If you experience sudden decrease or loss of vision, stop taking Vizarsin and contact your doctor immediately. You should not use Vizarsin with any other oral or local treatments for erectile dysfunction. You should not use Vizarsin with treatments for pulmonary arterial hypertension (PAH) containing sildenafil or any other PDE5 inhibitors. You should not take Vizarsin if you do not have erectile dysfunction. You should not take Vizarsin if you are a woman. Special considerations for patients with kidney or liver problems You should tell your doctor if you have kidney or liver problems. Your doctor may decide on a lower dose for you. Children and adolescents Vizarsin should not be given to individuals under the age of 18. Other medicines and Vizarsin Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Vizarsin tablets may interfere with some medicines, especially those used to treat chest pain. In the event of a medical emergency, you should tell your doctor, pharmacist or nurse that you have taken Vizarsin and when you did. Do not take Vizarsin with other medicines unless your doctor tells you that you can. You should not take Vizarsin if you are taking medicines called nitrates, as the combination of these medicines may lead to a dangerous fall in your blood pressure. Always tell your doctor, pharmacist or nurse if you are taking any of these medicines that are often used for the relief of angina pectoris (or chest pain ). You should not take Vizarsin if you are using any of the medicines known as nitric oxide donors such as amyl nitrite ( poppers ) as the combination may also lead to a dangerous fall in your blood pressure. Tell your doctor or pharmacist if you are already taking riociguat. If you are taking medicines known as protease inhibitors, such as for the treatment of HIV, your doctor may start you on the lowest dose (25 mg) of Vizarsin. Some patients who take alpha-blocker therapy for the treatment of high blood pressure or prostate enlargement may experience dizziness or light-headedness, which may be caused by low blood pressure upon sitting or standing up quickly. Certain patients have experienced these symptoms when taking Vizarsin with alpha-blockers. This is most likely to happen within 4 hours after taking Vizarsin. To reduce the chance that these symptoms might happen, you should be on a regular daily dose of your alpha-blocker before you start Vizarsin. Your doctor may start you on a lower dose (25 mg) of Vizarsin. Tell your doctor or pharmacist if you are taking medicines containing sacubitril/valsartan, used to treat heart failure. Vizarsin with food, drink and alcohol Vizarsin can be taken with or without food. However, you may find that Vizarsin takes longer to start working if you take it with a heavy meal. Drinking alcohol can temporarily impair your ability to get an erection. To get the maximum benefit from your medicine, you are advised not to drink excessive amounts of alcohol before taking Vizarsin. Pregnancy and breast-feeding Vizarsin is not indicated for use by women. Driving and using machines Vizarsin can cause dizziness and can affect vision. You should be aware of how you react to Vizarsin before you drive or use machinery. Vizarsin contains lactose and sodium If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .</p></div>
</text>
</section>
<section>
<title value="3. How to take vizarsin"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take vizarsin"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The recommended starting dose is 50 mg. You should not take Vizarsin more than once a day. You should take Vizarsin about one hour before you plan to have sex. Swallow the tablet whole with a glass of water. If you feel that the effect of Vizarsin is too strong or too weak, talk to your doctor or pharmacist. Vizarsin will only help you to get an erection if you are sexually stimulated. The amount of time Vizarsin takes to work varies from person to person, but it normally takes between half an hour and one hour. You may find that Vizarsin takes longer to work if you take it with a heavy meal. If Vizarsin does not help you to get an erection, or if your erection does not last long enough for you to complete sexual intercourse you should tell your doctor. If you take more Vizarsin than you should You may experience an increase in side effects and their severity. Doses above 100 mg do not increase the efficacy. You should not take more tablets than your doctor tells you to. Contact your doctor if you take more tablets than you should. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><h2 id="like-all-medicines-this-medicine-can-cause-side-effects-although-not-everybody-gets-them-the-side-effects-reported-in-association-with-the-use-of-vizarsin-are-usually-mild-to-moderate-and-of-a-short-duration-if-you-experience-any-of-the-following-serious-side-effects-stop-taking-vizarsin-and-seek-medical-help-immediately">Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects reported in association with the use of Vizarsin are usually mild to moderate and of a short duration. If you experience any of the following serious side effects stop taking Vizarsin and seek medical help immediately:</h2><h2 id="an-allergic-reaction---this-occurs-uncommonly-may-affect-up-to-1-in-100-people-symptoms-include-sudden-wheeziness-difficulty-in-breathing-or-dizziness-swelling-of-the-eyelids-face-lips-or-throat">An allergic reaction - this occurs uncommonly (may affect up to 1 in 100 people) Symptoms include sudden wheeziness, difficulty in breathing or dizziness, swelling of the eyelids, face, lips or throat.</h2><h2 id="chest-pains---this-occurs-uncommonly-if-this-occurs-during-or-after-intercourse">Chest pains - this occurs uncommonly If this occurs during or after intercourse:</h2><h2 id="get-in-a-semi-sitting-position-and-try-to-relax">Get in a semi-sitting position and try to relax.</h2><h2 id="do-not-use-nitrates-to-treat-your-chest-pain">Do not use nitrates to treat your chest pain.</h2><h2 id="prolonged-and-sometimes-painful-erections---this-occurs-rarely-may-affect-up-to-1-in-1people-if-you-have-an-erection-which-lasts-for-more-than-4-hours-you-should-contact-a-doctor-immediately">Prolonged and sometimes painful erections - this occurs rarely (may affect up to 1 in 1,people) If you have an erection which lasts for more than 4 hours, you should contact a doctor immediately.</h2><h2 id="a-sudden-decrease-or-loss-of-vision---this-occurs-rarely">A sudden decrease or loss of vision - this occurs rarely</h2><h2 id="serious-skin-reactions---this-occurs-rarely-symptoms-may-include-severe-peeling-and-swelling-of-the-skin-blistering-of-the-mouth-genitals-and-around-the-eyes-fever">Serious skin reactions - this occurs rarely Symptoms may include severe peeling and swelling of the skin, blistering of the mouth, genitals and around the eyes, fever.</h2><p>Seizures or fits - this occurs rarely Other side effects: Very common (may affect more than 1 in 10 people): headache. Common (may affect up to 1 in 10 people): nausea, facial flushing, hot flush (symptoms include a sudden feeling of heat in your upper body), indigestion, colour tinge to vision, blurred vision, visual disturbance, stuffy nose and dizziness. Uncommon (may affect up to 1 in 100 people): vomiting, skin rash, eye irritation, bloodshot eyes /red eyes, eye pain, seeing flashes of light, visual brightness, light sensitivity, watery eyes, pounding heartbeat, rapid heartbeat, high blood pressure, low blood pressure, muscle pain, feeling sleepy, reduced sense of touch, vertigo, ringing in the ears, dry mouth, blocked or stuffy sinuses, inflammation of the lining of the nose (symptoms include runny nose, sneezing and stuffy nose), upper abdominal pain, gastro-oesophageal reflux disease (symptoms include heartburn), presence of blood in urine, pain in the arms or legs, nosebleed, feeling hot and feeling tired. Rare (may affect up to 1 in 1000 people): fainting, stroke, heart attack, irregular heartbeat, temporary decreased blood flow to parts of the brain, feeling of tightening of the throat, numb mouth, bleeding at the back of the eye, double vision, reduced sharpness of vision, abnormal sensation in the eye, swelling of the eye or eyelid, small particles or spots in your vision, seeing halos around lights, dilation of the pupil of the eye, discolouration of the white of the eye, penile bleeding, presence of blood in semen, dry nose, swelling of the inside of the nose, feeling irritable and sudden decrease or loss of hearing. From post-marketing experience cases of unstable angina (a heart condition) and sudden death have been reported rarely. Of note, most but not all, of the men who experienced these side effects had heart problems before taking this medicine. It is not possible to determine whether these events were directly related to Vizarsin. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store vizarsin"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store vizarsin"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the box and blister after EXP. The expiry date refers to the last day of that month. This medicine does not require any special storage conditions. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><h2 id="what-vizarsin-contains">What Vizarsin contains</h2><h2 id="the-active-substance-is-sildenafil-each-film-coated-tablet-contains-sildenafil-citrate-equivalent-to-25-mg-sildenafil">The active substance is sildenafil. Each film-coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil.</h2><p>The other ingredients are: Tablet core: microcrystalline cellulose (E460), calcium hydrogen phosphate, croscarmellose sodium, hypromellose (E464), magnesium stearate (E470b). Film coating: lactose monohydrate, hypromellose (E464), titanium dioxide (E171), triacetin (E1518). See section 2 Vizarsin contains lactose and sodium . What Vizarsin looks like and contents of the pack Vizarsin 25 mg film-coated tablets are white, oblong and marked 25 on one side. Vizarsin 25 mg film-coated tablets are available in boxes of 1 film-coated tablet in blisters and also in boxes of 4 x 1, 8 x 1 or 12 x 1 film-coated tablet in a perforated unit dose blisters. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer KRKA, d.d., Novo mesto, marje ka cesta 6, 8501 Novo mesto, Slovenia For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien KRKA Belgium, SA. T l/Tel: + 32 (0) 487 50 73 Lietuva UAB KRKA Lietuva Tel: + 370 5 236 27</p><p>Te .: + 359 (02) 962 34 Luxembourg/Luxemburg KRKA Belgium, SA. T l/Tel: + 32 (0) 487 50 73 62 (BE) esk republika KRKA R, s.r.o. Tel: + 420 (0) 221 115 Magyarorsz g KRKA Magyarorsz g Kereskedelmi Kft. Tel.: + 36 (1) 355 8Danmark KRKA Sverige AB Tlf: + 46 (0)8 643 67 66 (SE) Malta E. J. Busuttil Ltd. Tel: + 356 21 445 Deutschland TAD Pharma GmbH Tel: + 49 (0) 4721 606-0 Nederland KRKA Belgium, SA. Tel: + 32 (0) 487 50 73 62 (BE) Eesti KRKA, d.d., Novo mesto Eesti filiaal Tel: + 372 (0) 6 671 Norge KRKA Sverige AB Tlf: + 46 (0)8 643 67 66 (SE)</p><p>KRKA<br/>: + 30 2100101 sterreich KRKA Pharma GmbH, Wien Tel: + 43 (0)1 66 24 Espa a KERN PHARMA, S.L. Tel: + 34 93 700 25 Polska KRKA-POLSKA Sp. z o.o. Tel.: + 48 (0)22 573 7France KRKA France Eurl T l: + 33 (0)1 57 40 82 Portugal KRKA Farmac utica, Sociedade Unipessoal Lda. Tel: + 351 (0)21 46 43 Hrvatska KRKA - FARMA d.o.o. Tel: + 385 1 6312 Rom nia KRKA Romania S.R.L., Bucharest Tel: + 4 021 310 66 Ireland KRKA Pharma Dublin, Ltd. Tel: + 353 1 413 3Slovenija KRKA, d.d., Novo mesto Tel: + 386 (0) 1 47 51 sland LYFIS ehf. S mi: + 354 534 3Slovensk republika KRKA Slovensko, s.r.o. Tel: + 421 (0) 2 571 04 Italia KRKA Farmaceutici Milano S.r.l. Tel: + 39 02 3300 8Suomi/Finland KRKA Finland Oy Puh/Tel: + 358 20 754 5 KI.PA. (PHARMACAL) LIMITED : + 357 24 651 Sverige KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) Latvija KRKA Latvija SIA Tel: + 371 6 733 86 United Kingdom (Northern Ireland) KRKA Pharma Dublin, Ltd. Tel: + 353 1 413 3This leaflet was last revised in Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp4f21ade1d3a44922f890a931e55ca9a9"/>
<resource>
<MedicinalProductDefinition>
<id value="mp4f21ade1d3a44922f890a931e55ca9a9"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp4f21ade1d3a44922f890a931e55ca9a9"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp4f21ade1d3a44922f890a931e55ca9a9</b></p><a name="mp4f21ade1d3a44922f890a931e55ca9a9"> </a><a name="hcmp4f21ade1d3a44922f890a931e55ca9a9"> </a><a name="mp4f21ade1d3a44922f890a931e55ca9a9-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/1 film-coated tablet: EU/1/09/551/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Vizarsin 25 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="1 film-coated tablet: EU/1/09/551/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Vizarsin 25 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
